Chabiotech Co.,Ltd.: debt-to-equity, ROE and more
KOSDAQ, Legal name Chabiotech Co.,Ltd.
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 214.8%
- Equity ratio
- 31.8%
- ROE
- -18.1%
- Op. margin
- -3.8%
- Rev. growth
- 21.4%
- Interest coverage
- n/a
Condition flags
- Latest operating profit is not above zero, or not reported.
- Operating loss for 4 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
No dividend data yet for this company.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 consolidated | 93.6% | 51.7% | -2.8% | 1.1% | n/a |
| FY2022 consolidated | 146.5% | 40.6% | -10.7% | -5.6% | 16.1% |
| FY2023 consolidated | 162.9% | 38.0% | -0.8% | -1.0% | 12.9% |
| FY2024 consolidated | 205.3% | 32.8% | -2.0% | -5.7% | 9.5% |
| FY2025 consolidated | 214.8% | 31.8% | -18.1% | -3.8% | 21.4% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩727.5B | ₩844.6B | ₩954.0B | ₩1.05T | ₩1.27T |
| Operating profit | ₩7.7B | -₩47.1B | -₩9.6B | -₩59.7B | -₩48.8B |
| Pre-tax income | -₩10.0B | -₩71.3B | ₩3.2B | -₩6.2B | -₩143.3B |
| Net income | -₩21.8B | -₩69.7B | -₩5.6B | -₩14.6B | -₩146.7B |
| Total assets | ₩1.54T | ₩1.61T | ₩1.73T | ₩2.19T | ₩2.55T |
| Total liabilities | ₩742.0B | ₩955.1B | ₩1.07T | ₩1.48T | ₩1.74T |
| Total equity | ₩793.1B | ₩651.9B | ₩656.3B | ₩718.8B | ₩809.2B |
| Paid-in capital | ₩28.1B | ₩28.1B | ₩28.2B | ₩28.2B | ₩39.7B |
| Debt/equity (source value) | 93.6% | 146.5% | 162.9% | 205.3% | 214.8% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 2002-11-05
- Listed
- 05/12/27
- Employees
- 354
- Auditor
- 대주회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1345110065662
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 차바이오텍Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.